Obinutuzumab as a Promising Treatment for Membranous Nephropathy.
作者信息
Meena Priti, Ramachandran Raja
机构信息
Department of Nephrology, All India Institute of Medical Sciences, Bhubaneshwar, Odisha, India.
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Nephrol. 2025 May-Jun;35(3):322-323. doi: 10.25259/IJN_391_2024. Epub 2024 Oct 10.
Abstract
摘要
相似文献
1
Obinutuzumab as a Promising Treatment for Membranous Nephropathy.奥妥珠单抗作为膜性肾病的一种有前景的治疗方法。
Indian J Nephrol. 2025 May-Jun;35(3):322-323. doi: 10.25259/IJN_391_2024. Epub 2024 Oct 10.
2
Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.奥妥珠单抗治疗利妥昔单抗耐药及复发性膜性肾病：病例系列
J Nephrol. 2025 Feb 20. doi: 10.1007/s40620-025-02224-6.
3
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.奥妥珠单抗和奥法木单抗在治疗伴有抗利妥昔单抗抗体的膜性肾病患者方面比利妥昔单抗更有效。
Kidney Int Rep. 2024 Dec 17;10(3):753-761. doi: 10.1016/j.ekir.2024.12.012. eCollection 2025 Mar.
4
Membranous nephropathy associated with immunoglobulin G4-related disease successfully treated with obinutuzumab.用奥滨尤妥珠单抗成功治疗与免疫球蛋白G4相关疾病相关的膜性肾病。
Clin Kidney J. 2021 Dec 8;15(3):564-566. doi: 10.1093/ckj/sfab250. eCollection 2022 Mar.
5
Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.奥妥珠单抗治疗膜性肾病：COVID-19大流行期间的有效性和安全性问题
Clin Kidney J. 2024 Oct 4;17(11):sfae299. doi: 10.1093/ckj/sfae299. eCollection 2024 Nov.
6
Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.奥妥珠单抗对利妥昔单抗难治性磷脂酶A2受体相关膜性肾病的治疗有效。
Clin Kidney J. 2025 May 1;18(5):sfaf026. doi: 10.1093/ckj/sfaf026. eCollection 2025 May.
7
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.奥妥珠单抗与利妥昔单抗治疗难治性原发性膜性肾病的疗效比较
Nephrol Dial Transplant. 2025 Apr 28;40(5):978-986. doi: 10.1093/ndt/gfae230.
8
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series.奥妥珠单抗治疗难治性膜性肾病：病例系列
Kidney Med. 2024 Jun 18;6(8):100853. doi: 10.1016/j.xkme.2024.100853. eCollection 2024 Aug.
9
Obinutuzumab in untreated primary membranous nephropathy: An observational case series.奥滨尤妥珠单抗治疗未经治疗的原发性膜性肾病：一项观察性病例系列研究。
Nephrology (Carlton). 2024 Nov;29(11):709-716. doi: 10.1111/nep.14331. Epub 2024 Jun 3.
10
Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.奥妥珠单抗治疗膜性肾病：治疗领域的潜在变革者
Drugs Context. 2025 Feb 21;14. doi: 10.7573/dic.2024-9-1. eCollection 2025.
本文引用的文献
1
Obinutuzumab in Difficult to Treat Phospholipase A2 Receptor Positive Membranous Nephropathy: Our Experience at a Tertiary Care Center in North India.奥妥珠单抗治疗难治性磷脂酶A2受体阳性膜性肾病：我们在印度北部一家三级医疗中心的经验。
Indian J Nephrol. 2025 Jan-Feb;35(1):91-96. doi: 10.25259/ijn_498_23. Epub 2024 Jul 8.
2
Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.奥妥珠单抗用于原发性膜性肾病患者的一线或二线治疗。
Kidney Int Rep. 2024 May 13;9(8):2386-2398. doi: 10.1016/j.ekir.2024.05.004. eCollection 2024 Aug.
3
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series.奥妥珠单抗治疗难治性膜性肾病：病例系列
Kidney Med. 2024 Jun 18;6(8):100853. doi: 10.1016/j.xkme.2024.100853. eCollection 2024 Aug.
4
A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.一名患有 semaphorin 3b 相关膜性肾病的儿童在利妥昔单抗耐药后用奥滨尤妥珠单抗治疗有效。
Pediatr Nephrol. 2024 Jan;39(1):305-308. doi: 10.1007/s00467-023-06085-8. Epub 2023 Jul 19.
5
Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD.奥妥珠单抗治疗伴有严重慢性肾脏病的难治性磷脂酶A2受体相关膜性肾病
Kidney Int Rep. 2023 Jan 31;8(4):942-943. doi: 10.1016/j.ekir.2023.01.035. eCollection 2023 Apr.
6
From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?从 KDIGO 2012 到 KDIGO 2021 特发性膜性肾病指南：过去 10 年有哪些变化？
J Nephrol. 2023 Mar;36(2):551-561. doi: 10.1007/s40620-022-01493-9. Epub 2022 Nov 30.
7
Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy.奥妥珠单抗对难治性膜性肾病有效。
Kidney Int Rep. 2020 Jul 3;5(9):1515-1518. doi: 10.1016/j.ekir.2020.06.030. eCollection 2020 Sep.
8
Successful Treatment of Patients With Refractory PLAR-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases.奥滨尤妥珠单抗成功治疗难治性 PLAR 相关膜性肾病 3 例报告。
Am J Kidney Dis. 2020 Dec;76(6):883-888. doi: 10.1053/j.ajkd.2020.02.444. Epub 2020 Apr 18.
9
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
10
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.针对 CD20 的单克隆抗体的表位相互作用及其与功能特性的关系。
MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.
Zotero 插件